PMC:7253235 / 42101-42328 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1371","span":{"begin":111,"end":115},"obj":"Gene"},{"id":"1372","span":{"begin":117,"end":121},"obj":"Gene"},{"id":"1373","span":{"begin":122,"end":125},"obj":"Gene"},{"id":"1379","span":{"begin":38,"end":46},"obj":"Species"},{"id":"1408","span":{"begin":31,"end":37},"obj":"Disease"},{"id":"1409","span":{"begin":81,"end":87},"obj":"Disease"}],"attributes":[{"id":"A1371","pred":"tao:has_database_id","subj":"1371","obj":"Gene:2064"},{"id":"A1372","pred":"tao:has_database_id","subj":"1372","obj":"Gene:673"},{"id":"A1373","pred":"tao:has_database_id","subj":"1373","obj":"Gene:5609"},{"id":"A1379","pred":"tao:has_database_id","subj":"1379","obj":"Tax:9606"},{"id":"A1408","pred":"tao:has_database_id","subj":"1408","obj":"MESH:D009369"},{"id":"A1409","pred":"tao:has_database_id","subj":"1409","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T422","span":{"begin":31,"end":37},"obj":"Disease"},{"id":"T423","span":{"begin":81,"end":87},"obj":"Disease"}],"attributes":[{"id":"A422","pred":"mondo_id","subj":"T422","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A423","pred":"mondo_id","subj":"T423","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T117","span":{"begin":122,"end":125},"obj":"Chemical"}],"attributes":[{"id":"A117","pred":"chebi_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/CHEBI_28398"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T235","span":{"begin":31,"end":37},"obj":"Phenotype"},{"id":"T236","span":{"begin":81,"end":87},"obj":"Phenotype"}],"attributes":[{"id":"A235","pred":"hp_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A236","pred":"hp_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T267","span":{"begin":0,"end":227},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)"}